Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Date:6/30/2008

Company's End-of-Phase II Meeting with FDA Set for Sept. 29

LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead AMPA/kainate-type glutamate receptor antagonist, tezampanel, demonstrated improvement on important secondary endpoints in a 306-patient Phase IIb clinical trial in acute migraine headache. Specifically, tezampanel demonstrated improvement in the following secondary endpoints: sustained headache response, absence of nausea or vomiting, absence of phonophobia and absence of photophobia.

"This is our second positive study in acute migraine with tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics, who presented the data. "In both studies, we have shown improvement in all of the endpoints that the FDA has indicated will be required for the drug's approval. Earlier this year we conducted a clinical guidance call with the FDA in which the agency said it has no objection with us moving forward with a Phase III study of the 40 mg dose of tezampanel. We have scheduled an end-of-Phase II meeting to discuss the entire Phase III program with the agency on Sept. 29."

In the Phase IIb clinical trial, tezampanel was well tolerated with no reports of serious or medically important adverse events. At the 40 mg dose, the most commonly reported adverse events compared to placebo were injection site pain (5.1 percent vs. 20 percent), injection site burning (3.8 percent vs. 6.7 percent), dizziness (6.4 percent vs. 5.3 percen
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 , La ... contribuye a adquirir tolerancia a la proteína de ... proteína de la leche de la vaca (APLV) es la ... Hasta ahora, la APLV se trataba eliminando las ... demostrado que es posible adquirir tolerancia oral en ...
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014 /PRNewswire/ ... rehydration solution (ORS), announced that it was awarded ... the leading healthcare services company that serves the ... Inc., UHC, Children,s Hospital Association and Provista.  ... designation based on feedback from member hospitals who ...
(Date:10/30/2014)... , Oct. 29, 2014 nebulizer is ... disorders (asthma, COPD and cystic fibrosis) that converts liquid ... easily reach into the lungs of a patient when ... global nebulizers market is dominated by various devices powered ... increasing prevalence of asthma, COPD and cystic fibrosis and ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 2010 Palatin Technologies, Inc. (NYSE Amex: PTN ... (the "Exchange"), advising Palatin that it is not in compliance ... Section 1003 of the Exchange,s Company Guide. In ... not in compliance with Section 1003(a)(iii) of the Company Guide ...
... 2, 2010 The Harley Medical Group is reporting a ... as an early present for themselves, the month before Christmas. ... to ensure a full recovery is made before they return ... procedures for Christmas 2010 include: Breast enlargement , Nose ...
Cached Medicine Technology:Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 2Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 3The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas 2
(Date:10/30/2014)... October 30, 2014 Five months after ... Hodgkinson Street LLC announces new branding and a website ... Mepham . After David Mepham’s promotion to name partner ... and website to include Mepham’s name and better reflect ... and mediation firm, the decision to implement new branding ...
(Date:10/30/2014)... Haelle HealthDay Reporter , ... 100 genes have been identified that appear linked to ... researchers say they are on their way to discovering ... the disorder. Autism spectrum disorders include a range ... and repetitive behaviors. An estimated one in 68 U.S. ...
(Date:10/30/2014)... Global prebiotics market is expected to reach ... study by Grand View Research, Inc. Positive outlook on ... fat free products owing to increased concerns over obesity ... the forecast period. , View full report with TOC ... was the largest application segment with market volume of ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... lots of milk could be bad for your health, a ... calcium in milk can help strengthen bones and prevent osteoporosis. ... to recommend milk as part of a healthy diet. ... milk did not protect men or women from bone fractures, ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... , PITTSBURGH, July 27 Childhood obesity ... adults and can lead to premature death in adulthood due ... In addition to its significant human toll, childhood obesity alone ... , , To address the continued tide ...
... survey of men who opt out of aggressive treatment ... delay treatment for their early prostate cancer are not ... research shows. , The evidence seems to contradict the ... for most patients, according to Dr. Roderick van den ...
... YORK, July 27 Paradigm Spine, LLC, a developer of ... a $21.5 million financing, consisting of a $15mm debt facility ... lender in the $15mm venture debt funding. The $6.5 ... asset management group specializing in high-growth opportunities, and Trevi Health ...
... ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ... (Vocus) July 27, ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ...
... , , , ... tell people,s personalities based on the types of drink they enjoy. ... as sweet and indulgent, while someone who likes fruity drinks could be ... Angeles-based BLD & Grace Restaurants says the same could be said for ...
... Spanish . Capsule endoscopy for exploring ... all lesions located by means of conventional colonoscopy. According to ... Medicine the specialised medical journal with greatest international ... achieve similar efficacy to the conventional procedure undertaken with a ...
Cached Medicine News:Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Most Not Worried by Delayed Prostate Cancer Therapy 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 3Health News:Minnesotans to Keynote Materials for Medical Devices Conference 2Health News:Personality in a Cup 2Health News:Personality in a Cup 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 2Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 4Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: